MX9802129A - Anticuerpo monoclonal br110 y usos del mismo. - Google Patents

Anticuerpo monoclonal br110 y usos del mismo.

Info

Publication number
MX9802129A
MX9802129A MX9802129A MX9802129A MX9802129A MX 9802129 A MX9802129 A MX 9802129A MX 9802129 A MX9802129 A MX 9802129A MX 9802129 A MX9802129 A MX 9802129A MX 9802129 A MX9802129 A MX 9802129A
Authority
MX
Mexico
Prior art keywords
antigen
monoclonal antibody
complex
ligands
ligand
Prior art date
Application number
MX9802129A
Other languages
English (en)
Other versions
MXPA98002129A (es
Inventor
Karl Erik Hellstrom
Ingegerd Hellstrom
Ursula Garrigues
Stephen Mcandrew
Hans Marquardt
Original Assignee
Bristol Myers Squib Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squib Company filed Critical Bristol Myers Squib Company
Publication of MX9802129A publication Critical patent/MX9802129A/es
Publication of MXPA98002129A publication Critical patent/MXPA98002129A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion proporciona ligandos interiorizantes (es decir, ligandos de BR110) que específicamente reconocen y se unen al antígeno BR110. Después de unirse al antígeno, el ligando y el antígeno forman un complejo. Como un complejo, el antígeno puede ser detectado usando métodos y sistemas comerciales muy conocidos y desarrollados.
MXPA/A/1998/002129A 1995-10-19 1998-03-18 Anticuerpo monoclonal br110 y usos del mismo MXPA98002129A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US564195P 1995-10-19 1995-10-19
US005641 1995-10-19
PCT/US1996/016070 WO1997014796A1 (en) 1995-10-19 1996-10-07 Monoclonal antibody br110 and uses thereof

Publications (2)

Publication Number Publication Date
MX9802129A true MX9802129A (es) 1998-05-31
MXPA98002129A MXPA98002129A (es) 1998-10-23

Family

ID=

Also Published As

Publication number Publication date
DE69632333T2 (de) 2004-12-30
DE69632333D1 (de) 2004-06-03
AU7394296A (en) 1997-05-07
EP0856054A1 (en) 1998-08-05
NO981745D0 (no) 1998-04-17
NO321548B1 (no) 2006-05-29
NO981745L (no) 1998-04-17
CA2235269C (en) 2006-09-19
EP0856054B1 (en) 2004-04-28
US5840854A (en) 1998-11-24
JP2001501801A (ja) 2001-02-13
WO1997014796A1 (en) 1997-04-24
IL123294A0 (en) 1998-09-24
ES2219699T3 (es) 2004-12-01
CA2235269A1 (en) 1997-04-24
ATE265532T1 (de) 2004-05-15

Similar Documents

Publication Publication Date Title
IL123294A0 (en) Monoclonal antibody BR110 and uses thereof
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
AU6954398A (en) Antagonistic anti-avb3 integrin antibodies
EP0724456A4 (en) ANTIBODIES AGAINST CD40
AU2001257012A1 (en) Methods for selective targeting
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
AU688953B2 (en) Determination of a specific immunoglobulin using multiple antigens
CA2442182A1 (en) Modulation of pd-1 interactions with its ligands
WO2004025248A3 (en) Antibody pair screening methods
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
ATE248859T1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
AU4441799A (en) Monoclonal antibodies that recognize antigens associated with tumor metastasis
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
IL108607A0 (en) Preparation of photoprotein conjugates and methods of use thereof
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
GB9623531D0 (en) Sheets,kits and methods for detecting antigens or antibodies
AU5924699A (en) Methods for identifying hot-spot residues of binding proteins and small compounds that bind to the same
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
NO20001051D0 (no) Monoklonale antistoffer som binder testosteron
AU6068000A (en) Peptide ligands that bind igm antibodies and block interaction with antigen
Loy et al. Correspondence re: TS Loy, AA Diaz-Arias, JT Bickel. Value of BCA-225 in the cytologic diagnosis of malignant effusions: an immunocytochemical study of 197 cases. Mod Pathol 3: 294, 1990